Correction: Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5A receptor inhibitor, based on preclinical evaluation and randomized phase 1 clinical study (PLoS ONE (2016) 11: 10 (e0164646) DOI: 10.1371/journal.pone.0164646);Characterization of pharmacologic and pharmacokinetic properties of CCX168, a potent and selective orally administered complement 5a receptor inhibitor, based on preclinical evaluation and randomized Phase 1 clinical study

PLoS ONE

Volumn 11, Issue 10, 2016, Pages

  Bekker, Pirow ^a   Dairaghi, Daniel ^a   Seitz, Lisa ^a   Leleti, Manmohan ^a   Wang, Yu ^a   Ertl, Linda ^a   Baumgart, Trageen ^a   Shugarts, Sarah ^a   Lohr, Lisa ^a   Dang, Ton ^a   Miao, Shichang ^a   Zeng, Yibin ^a   Fan, Pingchen ^a   Zhang, Penglie ^a   Johnson, Daniel ^a   Powers, Jay ^a   Jaen, Juan ^a   Charo, Israel ^a   Schall, Thomas J ^a  

^a ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVACOPAN; CD11B ANTIGEN; PLACEBO; ANILINE DERIVATIVE; COMPLEMENT COMPONENT C5A RECEPTOR; NIPECOTIC ACID DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM MOBILIZATION; CELL MIGRATION; CHEMOTAXIS; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LEUKOPENIA; LOWER ABDOMINAL PAIN; MACACA FASCICULARIS; MALE; MOUSE; NAUSEA; NONHUMAN; NORMAL HUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RAT; SINGLE DRUG DOSE; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; TRANSGENIC MOUSE; U-937 CELL LINE;

ADMINISTRATION, ORAL; ANILINE COMPOUNDS; ANIMALS; HEALTHY VOLUNTEERS; HUMANS; MACACA FASCICULARIS; MICE; MICE, TRANSGENIC; NIPECOTIC ACIDS; RECEPTOR, ANAPHYLATOXIN C5A; U937 CELLS;

EID: 84992349076     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0210593     Document Type: Erratum

References (30)

1. Speth C, Prodinger W, Wurzner R, Stoiber H, Dierich M. Complement. In: Paul WE, editor. Fundamental Immunology. Sixth ed. Philadelphia, PA: Lippincott Williams & Wilkins. 2008. pp. 1047-1078.
2. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol. 2005; 23:821-852. doi: 10.1146/annurev.immunol.23.021704.115835 PMID: 15771587
3. Sahu A, Lambris JD. Complement inhibitors: a resurgent concept in anti-inflammatory therapeutics. Immunopharmacol. 2000; 49:133-148.
4. Powers JP, Dairaghi DJ, Jaen JC. Advances in the discovery of C5a receptor antagonists. Ann Reports Med Chem. 2011; 46:171-186.
5. Ricklin D, Lambris JD. Progress and trends in complement therapeutics. Adv Exp Med Biol 2013; 735:1-22.
6. Woodruff TM, Nandakumar KS, Tedesco F. Inhibiting the C5-C5a receptor axis. Mol Immunol. 2011; 48:1631-1642. doi: 10.1016/j.molimm.2011.04.014 PMID: 21549429
7. Höpken UE, Bao Lu, Gerard NP, Gerard C. Impaired inflammatory responses in the reverse Arthus reaction through genetic deletion of the C5a receptor. J Exp Med. 1997; 186:749-775. PMID: 9271590
8. Gerard C, Gerard NP. C5a anaphylatoxin and its seven transmembrane segment receptor. Annu Rev Immunol. 1994; 12:775-808. doi: 10.1146/annurev.iy.12.040194.004015 PMID: 8011297
9. Gerard NP, Gerard C. The chemotactic receptor for human C5a anaphylatoxin. Nature. 1991 349:614-617. doi: 10.1038/349614a0 PMID: 1847994
10. Figueroa JE and Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev. 1991; 4:359-395. PMID: 1889047
11. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Pharmacology. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors. Pharmacol Rev. 2013; 65: 500-543.
12. Monk PN, Scola AM, Madala P, Fairlie DP. Function, structure and therapeutic potential of complement C5a receptors. Br J Pharmacol. 2007; 152:429-448. doi: 10.1038/sj.bjp.0707332 PMID: 17603557
13. Cain SA, Monk PN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem 2002; 277:7165-7169. doi: 10.1074/jbc.C100714200 PMID: 11773063
14. Okinaga S, Slattery D, Humbles A, Zsengeller Z, Morteau O, Kinrade MB, et al. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003; 42:9406-9415. doi: 10.1021/bi034489v PMID: 12899627
15. Gerard NP, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S, et al. (2005) An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J Biol Chem. 2005; 280:39677-39680. doi: 10.1074/jbc.C500287200 PMID: 16204243
16. Lee H, Whitfeld PL, Mackay CR. Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2. Immunol Cell Biol. 2008; 86:153-160. doi: 10.1038/sj.icb.7100166 PMID: 18227853
17. Scola AM, Johswich KO, Morgan BP, Klos A, Monk PN. The human complement fragment receptor, C5L2, is a recycling decoy receptor. Mol Immunol. 2009; 46:1149-1162. doi: 10.1016/j.molimm.2008. 11.001 PMID: 19100624
18. Ricklin D, Lambris JD. Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol. 2013; 190:3831-3838. doi: 10.4049/jimmunol.1203487 PMID: 23564577
19. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014; 25:225-231. doi: 10.1681/ASN. 2013020143 PMID: 24179165
20. Jennette JC, Falk RJ, Hu P, Xiao H. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol. 2013; 8:139-160. doi: 10.1146/annurev-pathol-011811-132453 PMID: 23347350
21. Schreiber A, Xiao H, Jennette JC, Schneider W, Luft FC, Kettritz R. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol. 2009; 20:289-298. doi: 10.1681/ASN.2008050497 PMID: 19073822
22. Monk P, Partridge L. Characterization of a complement-fragment-C5a-stimulated calcium-flux mechanism in U937 monocytic cells. Biochem J. 1993; 295:679-684. PMID: 8240277
23. Dairaghi DJ, Fan RA, McMaster BE, Hanley MR, Schall TJ. HHV8-encoded vMIP-I selectively engages chemokine receptor CCR8. J Biol Chem. 1999; 274:21569-21574. PMID: 10419462
24. Dairaghi DJ, Zhang P, Wang Y, Seitz LC, Johnson DA, Miao S, et al. Pharmacokinetic and pharmacodynamic evaluation of the novel CCR1 antagonist CCX354 in healthy human subjects: implications for selection of clinical dose. Clin Pharmacol Ther 2011; 89:726-734. doi: 10.1038/clpt.2011.33 PMID: 21451509
25. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, et al. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2010; 335:61-69. doi: 10.1124/jpet.110.169714 PMID: 20660125
26. Elsner J, Oppermann M, Czech W, Kapp A. C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins. Blood 1994; 83:3324-3331. PMID: 8193368
27. Brodbeck RM, Cortright DN, Kieltyka AP, Yu J, Baltazar CO, Buck ME, et al. Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanamine], a novel, orally bioavailable C5a receptor inverse agonist. J Pharmacol Exp Ther. 2008; 327:898-909. doi: 10.1124/jpet.108.141572 PMID: 18753409
28. Gou S-J, Yuan J, Chen M, Yu F, Zhao M-H. Circulating complement activation in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2012; 83:129-137. doi: 10.1038/ki. 2012.313 PMID: 22913983
29. Kronbichler A, Kerschbaum J, Gründlinger G, Leierer J, Mayer G, Rudnicki M. Evaluation and validation of biomarkers in granulomatosis with polyangiitis and microscopic polyangiitis. Nephrol Dial Transplant. 2016; 31:930-936. doi: 10.1093/ndt/gfv336 PMID: 26410887
30. Waters SM, Brodbeck RM, Steflik J, Yu J, Baltazar C, Peck AE, et al. Molecular characterization of the gerbil C5a receptor and identification of a transmembrane domain V amino acid that is crucial for small molecule antagonist. J Biol Chem. 2005; 280:40617-40623. doi: 10.1074/jbc.M509245200 PMID: 16230349